Downstream Processing Featured Articles

41. New Laboratory Technique Captures microRNA Targets 5/9/2012

    Human cells are thought to produce thousands of different microRNAs (miRNAs)—small pieces of genetic material that help determine which genes are turned on or off at a given time.

42. The Process Behind The Potential: Therapy For HPV16-Related Malignancies 2/18/2020

    HPV-related malignancies are poised to skyrocket over the next thirty+ years. Here's a look into Cue Biopharma’s engineering-centric approach to in vivo tumor antigen specific T cell activation to treat these cancers.

43. 3 Factors To Prevent Protein Aggregation For Your Protein Purification Buffer

    Before you purify your first batch of a new protein it is important to know what buffer you might want to use to keep precipitation of proteins to a minimum.

44. Successful Immunization And Safety Documented In Nasal Administration Study Of The HIV Vaccine Vacc-4x Together With Endocine 5/10/2012

    Bionor Pharma ASA (OSLO: BIONOR), Eurocine Vaccines AB and Oslo University Hospital today announced that vaccine related immune responses are documented in patients given active vaccine in a nasal immunization study, combining Bionor Pharma's Vacc-4x and Eurocine Vaccines' adjuvant Endocine.

45. New' Estrogen Receptor Found To Be Key Player In Tamoxifen Resistance 10/31/2008
    Researchers at Georgetown University Medical Center have discovered a novel way in which breast cancer cells become resistant to tamoxifen, the world's largest-selling breast cancer prevention and treatment drug.
46. GeoVax Announces Enrollment Completion For Phase 1/2 Clinical Trial For HIV/AIDS Therapeutic Vaccine 1/10/2013

    GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, announced it has completed enrollment in a nine-patient Phase 1/2 clinical trial testing the safety, immunogenicity and ability of its DNA/MVA vaccine to elicit protective immune responses in HIV-infected individuals.

47. Crucell And Scripps Research Discover And Describe Broad-Spectrum Antibodies Against Influenza B, A Crucial Link In Development Of Universal Flu Therapies And Vaccine 8/9/2012

    In a landmark discovery, researchers from Crucell Holland B.V. and The Scripps Research Institute, recently announced the identification of the first human monoclonal antibodies that appear capable of disabling all influenza B viruses. 

48. Paired Genes In Stem Cells Shed New Light On Gene Organization And Regulation 2/4/2013

    Whitehead Institute researchers have determined that DNA transcription, the process that produces messenger RNA (mRNA) templates used in protein production, also runs in the opposite direction along the DNA to create corresponding long noncoding RNAs (lncRNAs). By Nicole Giese Rura

49. New Look At Multitalented Protein Sheds Light On Mysteries Of HIV 11/12/2012

    New insights into the human immunodeficiency virus (HIV) infection process, which leads to acquired immunodeficiency syndrome (AIDS), may now be possible through a research method recently developed in part at the National Institute of Standards and Technology (NIST), where scientists have glimpsed an important protein molecule's behavior with unprecedented clarity.

50. International Stem Cell Corporation Demonstrates Positive Animal Efficacy Results In Metabolic Liver Disease Program 2/12/2013

    International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company, today announced the conclusions from its study demonstrating the efficacy and safety of the hepatocyte-like cells (HLC) derived from human parthenogenetic stem cells (hpSC) in a well-established animal model of a congenital liver disorder associated with bilirubin metabolism.